Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beclometasone/formoterol - Chiesi Farmaceutici

Drug Profile

Beclometasone/formoterol - Chiesi Farmaceutici

Alternative Names: Beclomethasone/formoterol; CHF 1535 35/4 NEXTHALER®; CHF-1535; Combair; Formodual; Formoterol/beclometasone; Fostair; Fostair NEXThaler; Foster; Foster Nexthaler; Foster Spray; Fostex; Fostex NEXThaler; Innovair; Innovair NEXThaler; Inuvair; Inuver; Inuxair; Kantos; Kantos Master; Kantos NEXThaler

Latest Information Update: 29 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi Farmaceutici
  • Class Antiasthmatics; Corticosteroids; Ethanolamines; Pregnadienetriols; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 05 Feb 2019 Chemical structure information added
  • 21 Sep 2018 Chiesi initiates a phase II trial for Asthma in United Kingdom (Inhalation) (EudraCT2018-000353-50)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top